Overview

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Status:
RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

SHR-1701